140 related articles for article (PubMed ID: 17463174)
1. Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells.
Bremer S; Rootwelt H; Bergan S
Clin Chem; 2007 Jun; 53(6):1023-9. PubMed ID: 17463174
[TBL] [Abstract][Full Text] [Related]
2. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.
Bremer S; Mandla R; Vethe NT; Rasmussen I; Rootwelt H; Line PD; Midtvedt K; Bergan S
Transplantation; 2008 Jan; 85(1):55-61. PubMed ID: 18192912
[TBL] [Abstract][Full Text] [Related]
3. Expression of IMPDH1 is regulated in response to mycophenolate concentration.
Bremer S; Vethe NT; Rootwelt H; Bergan S
Int Immunopharmacol; 2009 Feb; 9(2):173-80. PubMed ID: 19010451
[TBL] [Abstract][Full Text] [Related]
4. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot study.
Bremer S; Vethe NT; Rootwelt H; Jørgensen PF; Stenstrøm J; Holdaas H; Midtvedt K; Bergan S
J Transl Med; 2009 Jul; 7():64. PubMed ID: 19635156
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
[TBL] [Abstract][Full Text] [Related]
8. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil.
Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P
Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients.
Langman LJ; LeGatt DF; Halloran PF; Yatscoff RW
Transplantation; 1996 Sep; 62(5):666-72. PubMed ID: 8830834
[TBL] [Abstract][Full Text] [Related]
10. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors.
Sintchak MD; Nimmesgern E
Immunopharmacology; 2000 May; 47(2-3):163-84. PubMed ID: 10878288
[TBL] [Abstract][Full Text] [Related]
11. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
12. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
13. Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.
Rath T; Küpper M
Transplant Proc; 2009; 41(6):2524-8. PubMed ID: 19715967
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of mycophenolate mofetil.
Ransom JT
Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
[TBL] [Abstract][Full Text] [Related]
15. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic monitoring of mycophenolate mofetil.
Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
[TBL] [Abstract][Full Text] [Related]
17. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
Vethe NT; Bergan S
Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
[TBL] [Abstract][Full Text] [Related]
19. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid.
Vethe NT; Ali AM; Reine PA; Andersen AM; Bremer S; Line PD; Rootwelt H; Bergan S
Ther Drug Monit; 2014 Feb; 36(1):108-18. PubMed ID: 24061448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
